178 related articles for article (PubMed ID: 38502889)
1. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
Gordan JD; Kennedy EB; Abou-Alfa GK; Beal E; Finn RS; Gade TP; Goff L; Gupta S; Guy J; Hoang HT; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Kortmansky J; Leaf A; Remak WM; Sohal DPS; Taddei TH; Wilson Woods A; Yarchoan M; Rose MG
J Clin Oncol; 2024 May; 42(15):1830-1850. PubMed ID: 38502889
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
Gordan JD; Kennedy EB; Abou-Alfa GK; Beg MS; Brower ST; Gade TP; Goff L; Gupta S; Guy J; Harris WP; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Knox JJ; Kortmansky J; Leaf A; Remak WM; Shroff RT; Sohal DPS; Taddei TH; Venepalli NK; Wilson A; Zhu AX; Rose MG
J Clin Oncol; 2020 Dec; 38(36):4317-4345. PubMed ID: 33197225
[TBL] [Abstract][Full Text] [Related]
3. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
[TBL] [Abstract][Full Text] [Related]
4. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
Tella SH; Kommalapati A; Mahipal A; Jin Z
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
[TBL] [Abstract][Full Text] [Related]
6. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
Su GL; Altayar O; O'Shea R; Shah R; Estfan B; Wenzell C; Sultan S; Falck-Ytter Y
Gastroenterology; 2022 Mar; 162(3):920-934. PubMed ID: 35210014
[TBL] [Abstract][Full Text] [Related]
7. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
[TBL] [Abstract][Full Text] [Related]
8. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
[TBL] [Abstract][Full Text] [Related]
9. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Kim DY
Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
[TBL] [Abstract][Full Text] [Related]
10. A concise review of the changing landscape of hepatocellular carcinoma.
Draper A
Am J Manag Care; 2020 Oct; 26(10 Suppl):S211-S219. PubMed ID: 33052638
[TBL] [Abstract][Full Text] [Related]
11. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
Cersosimo RJ
Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
[TBL] [Abstract][Full Text] [Related]
12. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma.
Rimassa L; Wörns MA
Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830
[TBL] [Abstract][Full Text] [Related]
13. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
Weinmann A; Galle PR
Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
[TBL] [Abstract][Full Text] [Related]
14. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors.
Piñero F; Silva M; Iavarone M
World J Gastroenterol; 2020 Apr; 26(16):1888-1900. PubMed ID: 32390700
[TBL] [Abstract][Full Text] [Related]
15. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Chen J; Wang J; Xie F
Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
[TBL] [Abstract][Full Text] [Related]
17. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
19. Current treatment options for hepatocellular carcinoma.
Eugen K
Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
[TBL] [Abstract][Full Text] [Related]
20. Molecular therapies for HCC: Looking outside the box.
Faivre S; Rimassa L; Finn RS
J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
